Tectonic Therapeutic, Inc. (TECX)
Nasdaq · Healthcare · Biotechnology
$23.11+2.53%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $452M
- 52-week range
- $14.60 – $39.53
- 52-week change
- +51.17%
- EPS (trailing)
- −$4.57
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Net income
- −$74.2B
- Diluted EPS
- −$4.05
- Free cash flow
- −$60.3M
From the company’s annual report on SEC EDGAR.
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Headquarters: Watertown, United States · 60 employees · tectonictx.com